Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Revenue: 2020-2025

Historic Revenue for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Sep 2025 value amounting to $133.0 million.

  • Mirum Pharmaceuticals' Revenue rose 47.17% to $133.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $471.8 million, marking a year-over-year increase of 53.66%. This contributed to the annual value of $336.9 million for FY2024, which is 80.76% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Revenue is $133.0 million, which was up 4.09% from $127.8 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Revenue ranged from a high of $133.0 million in Q3 2025 and a low of -$3.4 million during Q1 2021.
  • For the 3-year period, Mirum Pharmaceuticals' Revenue averaged around $81.4 million, with its median value being $77.9 million (2024).
  • Data for Mirum Pharmaceuticals' Revenue shows a peak YoY skyrocketed of 1,036.72% (in 2021) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' Revenue (Quarterly) stood at $3.1 million in 2021, then surged by 789.29% to $27.9 million in 2022, then surged by 149.24% to $69.6 million in 2023, then soared by 42.93% to $99.4 million in 2024, then surged by 47.17% to $133.0 million in 2025.
  • Its Revenue stands at $133.0 million for Q3 2025, versus $127.8 million for Q2 2025 and $111.6 million for Q1 2025.